First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology

Recent advances in understanding the mechanisms of nonsmall cell lung cancer (NSCLC) has led to the development of targeted treatments, including the reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib, and the irreversible ErbB family blocker afatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sebastian, Martin, Schmittel, Alexander, Reck, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2014
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487257/
https://www.ncbi.nlm.nih.gov/pubmed/24591666
http://dx.doi.org/10.1183/09059180.00008413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487257/
https://www.ncbi.nlm.nih.gov/pubmed/24591666
http://dx.doi.org/10.1183/09059180.00008413

Ejemplares similares